Abstract Details

Title The Syn-Q Study: Quantification of Phosphorylated Alpha-synuclein in Patients with Parkinson’s Disease and REM Sleep Behavior Disorder

Topic Movement Disorders

Presentation(s) P6 - Poster Session 6 (5:00 PM-6:00 PM)

Poster/Presentation
Number 16-007

Objective To define changes in cutaneous P-SYN quantification over 18 months in patients with Parkinson’s disease (PD) and idiopathic REM sleep behavior disorder (iRBD).

Background PD is characterized by progressive pathological alpha-synuclein (P-SYN) deposition in the central and peripheral nervous system. Skin biopsy has demonstrated high sensitivity and specificity for the detection of peripheral P-SYN in patients with PD. Recent technological advances now allow for quantitation of peripheral P-SYN, although longitudinal studies in PD have not been conducted.

Design/Methods After consent, participants with PD of Hoehn and Yahr stages 1, 2, 3 and iRBD completed neurological examinations, medical history, cognitive evaluation, motor assessments, olfactory testing (BSIT), orthostatic vitals, and neurodegenerative disease questionnaires. Skin biopsies taken from the distal leg, distal thigh, and posterior cervical sites were performed on all participants with blinded quantitation of P-SYN. Participants will return for follow-up visits at 6-month intervals following the baseline visit.

Results At the time of abstract submission, 80 patients completed baseline testing (PD stage I: n=18, 63.3±6.1 years, 10 female; PD stage II: n=25, 67.7±8.7 years, 12 female; PD stage III: n=22, 72.8±9.7 years, 10 female; RBD: n=15, 65.7±9.4 years, 5 female). Baseline P-SYN results were available in 72 patients and 63 (87.5%) were P-SYN positive. Analysis by disease severity revealed 10/11 (90.9%) iRBD patients were P-SYN positive, 15/18 (83.3%) in PD Stage I, 23/25 (92%) in PD Stage II, and 15/18 (83.3%) in Stage III patients were P-SYN positive. P-SYN quantitative assessment correlated with greater motor impairment, indicated by the UPDRS Pt. 3 (r=0.26, p=0.026).

Conclusions Cutaneous P-SYN was present in skin samples from patients with iRBD and in PD across Hoehn and Yahr stages 1-3. Preliminary data suggests a correlation between quantitative measures of P-SYN and disease severity. Longitudinal follow-up data collection is ongoing and will be reported at the 2026 AAN Meeting.

Authors/Disclosures
Christopher H. Gibbons, MD, FAAN (Beth Israel Deaconess Medical Center) PRESENTER	Dr. Gibbons has received personal compensation for serving as an employee of CND Life Sciences. Dr. Gibbons has or had stock in CND Life Sciences.Dr. Gibbons has received publishing royalties from a publication relating to health care.
Todd D. Levine, MD (Honor Health)	Dr. Levine has received personal compensation for serving as an employee of CND life sciences . Dr. Levine has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nufactor. Dr. Levine has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for PNA. Dr. Levine has or had stock in CND Life Sciences.Dr. Levine has or had stock in Corinthian reference lab.
Bailey Bellaire (CND Life Sciences)	Bailey Bellaire has received personal compensation for serving as an employee of CND Life Sciences.
Jourdan Parent, PhD	Dr. Parent has received personal compensation for serving as an employee of CND Life Sciences.
Sarrah Marcotte	Miss Marcotte has received personal compensation for serving as an employee of CND Life Sciences.
Manuel X. Duval, PhD	Mr. Duval has received personal compensation for serving as an employee of CND Life sciences.
Roy L. Freeman, MD (Beth Israel Deaconess Hosp)	Dr. Freeman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Cutaneous Diagnostic Life Sciences. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. Dr. Freeman has received research support from Regeneron.

��ɫ��

��ɫ��